The Flu Shot Drama at the FDA

The FDA's fluctuating stance on Moderna's new flu shot application highlights the agency's internal conflicts and evolving approach to drug approvals. The initial rejection, driven by a Trump-appointed regulator's concerns over trial design, sparked controversy and internal objections, especially given Moderna's reliance on mRNA technology and the potential for quicker flu vaccine development. This decision aligns with broader skepticism towards mRNA vaccines from figures like Robert F. Kennedy Jr., influencing the FDA's direction. The reversal came after White House and HHS intervention, potentially paving the way for the flu shot's availability by the 2026-2027 season. However, uncertainty persists within the pharmaceutical sector due to regulatory reversals, staff turnover, and concerns over the consistency of FDA decisions, particularly regarding rare disease drug approvals.

Outlines

Part 1: Flu Season, mRNA Technology

Part 2: Regulatory Shifts, Clinical Standards

Part 3: Rare Diseases, Industry Impact

Sign in to continue reading, translating and more.

Open full episode in Podwise

The Journal.

Part 1: Flu Season, mRNA Technology

The FDA's Flu Shot Controversy Amidst a Severe Flu Season

FDA's Initial Rejection and Subsequent Review of Moderna's Flu Shot Application

Moderna's mRNA Vaccine Technology and the Traditional Flu Vaccine Process

Part 2: Regulatory Shifts, Clinical Standards

FDA's Changing Standards for Flu Vaccine Approval and Moderna's Clinical Trials

Controversy Surrounding Dr. Vinay Prasad and His Skepticism of mRNA Vaccines

Vinay Prasad's Rocky Tenure at the FDA and Concerns Over Rare Disease Drug Approvals

Part 3: Rare Diseases, Industry Impact

Pierre Fabre's Rare Disease Treatment Rejection and FDA's Stance

FDA Reverses Course on Moderna's Flu Shot and Uncertainty in the Pharmaceutical Sector

Differing Opinions on FDA Reforms and Concerns About Drug Pricing Initiatives

The Flu Shot Drama at the FDA

The Journal.

Part 1: Flu Season, mRNA Technology

00:05The FDA's Flu Shot Controversy Amidst a Severe Flu Season

The FDA's Flu Shot Controversy Amidst a Severe Flu Season

00:52FDA's Initial Rejection and Subsequent Review of Moderna's Flu Shot Application

FDA's Initial Rejection and Subsequent Review of Moderna's Flu Shot Application

02:21Moderna's mRNA Vaccine Technology and the Traditional Flu Vaccine Process

Moderna's mRNA Vaccine Technology and the Traditional Flu Vaccine Process

Part 2: Regulatory Shifts, Clinical Standards

04:46FDA's Changing Standards for Flu Vaccine Approval and Moderna's Clinical Trials

FDA's Changing Standards for Flu Vaccine Approval and Moderna's Clinical Trials

07:36Controversy Surrounding Dr. Vinay Prasad and His Skepticism of mRNA Vaccines

Controversy Surrounding Dr. Vinay Prasad and His Skepticism of mRNA Vaccines

10:17Vinay Prasad's Rocky Tenure at the FDA and Concerns Over Rare Disease Drug Approvals

Vinay Prasad's Rocky Tenure at the FDA and Concerns Over Rare Disease Drug Approvals

Part 3: Rare Diseases, Industry Impact

13:07Pierre Fabre's Rare Disease Treatment Rejection and FDA's Stance

Pierre Fabre's Rare Disease Treatment Rejection and FDA's Stance

14:38FDA Reverses Course on Moderna's Flu Shot and Uncertainty in the Pharmaceutical Sector

FDA Reverses Course on Moderna's Flu Shot and Uncertainty in the Pharmaceutical Sector

17:20Differing Opinions on FDA Reforms and Concerns About Drug Pricing Initiatives

Differing Opinions on FDA Reforms and Concerns About Drug Pricing Initiatives